Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지
DOI QR코드

DOI QR Code

Diagnosis and Treatment of Gastric Neuroendocrine Tumors

위 신경내분비종양의 진단과 치료

  • Soo In Choi (Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine)
  • 최수인 (인제대학교 의과대학 상계백병원 내과학교실)
  • Received : 2022.04.29
  • Accepted : 2022.05.17
  • Published : 2022.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

The incidence of gastric neuroendocrine tumors (NET) has been increased with the improvement of endoscopy accessibility. The World Health Organization classified NET of low (G1), intermediate (G2), high (G3) grade and neuroendocrine carcinoma with poor differentiation by mitotic count and Ki-67 labeling index. Gastric NET are divided into three subtypes based on the pathophysiology, and treatment is determined according to the subtype and prognostic factors of tumor. For diagnosis, endoscopy with biopsy, endoscopic ultrasonography, abdominal pelvis computed tomography, and serum gastrin level measure are required. In general, type 3, size > 2 cm, deep submucosal infiltration, high histological grade, lymphovascular invasion and metastasis are poor prognostic factors. Type 1 or 2 without these factors are treated by endoscopic resection, and other tumors needs surgery. Endoscopic resection of early type 3 or type 1 and 2 tumors with poor prognostic factors still remains a challenge.

Keywords

References

  1. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.  https://doi.org/10.1016/S1470-2045(07)70410-2
  2. Williams ED, Sandler M. The classification of carcinoid tum ours. Lancet 1963;1:238-239.  https://doi.org/10.1016/S0140-6736(63)90951-6
  3. Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: International Agency for Research on Cancer, 2017. pp.1021-1044. 
  4. Kloppel G. Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma. Endocr Pathol 2007;18:141-144.  https://doi.org/10.1007/s12022-007-0021-9
  5. Yang Z, Wang W, Lu J, et al. Gastric neuroendocrine tumors (G-Nets): incidence, prognosis and recent trend toward improved survival. Cell Physiol Biochem 2018;45:389-396.  https://doi.org/10.1159/000486915
  6. Boyce M, Thomsen L. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist. Scand J Gastroenterol 2015;50:550-559.  https://doi.org/10.3109/00365521.2015.1009941
  7. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959.  https://doi.org/10.1002/cncr.11105
  8. Strosberg JR, Benson AB, Huynh L, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist 2014;19:930-936.  https://doi.org/10.1634/theoncologist.2014-0120
  9. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335-1342.  https://doi.org/10.1001/jamaoncol.2017.0589
  10. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104:994-1006.  https://doi.org/10.1016/0016-5085(93)90266-F
  11. Zhao CM, Chen D. The ECL cell: relay station for gastric integrity. Curr Med Chem 2012;19:98-108.  https://doi.org/10.2174/092986712803414060
  12. Gluckman CR, Metz DC. Gastric neuroendocrine tumors (carcinoids). Curr Gastroenterol Rep 2019;21:13. 
  13. Cadiot G, Laurent-Puig P, Thuille B, Lehy T, Mignon M, Olschwang S. Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome? Gastroenterology 1993;105:579-582.  https://doi.org/10.1016/0016-5085(93)90736-V
  14. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005;242:64-73.  https://doi.org/10.1097/01.sla.0000167862.52309.7d
  15. Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol 2013;168:185-193.  https://doi.org/10.1530/EJE-12-0836
  16. Tsolakis AV, Ragkousi A, Vujasinovic M, Kaltsas G, Daskalakis K. Gastric neuroendocrine neoplasms type 1: a systematic review and meta-analysis. World J Gastroenterol 2019;25:5376-5387.  https://doi.org/10.3748/wjg.v25.i35.5376
  17. Hosokawa O, Kaizaki Y, Hattori M, et al. Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer 2005;8:42-46.  https://doi.org/10.1007/s10120-004-0303-6
  18. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004;83:43-83. Erratum in: Medicine (Baltimore) 2004;83:175. 
  19. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996;20:168-172.  https://doi.org/10.1007/s002689900026
  20. Ruszniewski P, Delle Fave G, Cadiot G, et al. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology 2006;84:158-164.  https://doi.org/10.1159/000098007
  21. Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery 2004;136:1267-1274.  https://doi.org/10.1016/j.surg.2004.06.057
  22. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004;99:23-32.  https://doi.org/10.1046/j.1572-0241.2003.04027.x
  23. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.  https://doi.org/10.1007/s00428-006-0250-1
  24. Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract 2012;2012:287825. 
  25. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study. Int J Cancer 2008;123:867-873.  https://doi.org/10.1002/ijc.23529
  26. Kwon YH, Jeon SW, Kim GH, et al. Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol 2013;19:8703-8708.  https://doi.org/10.3748/wjg.v19.i46.8703
  27. Modlin IM, Sandor A, Tang LH, Kidd M, Zelterman D. A 40-year analysis of 265 gastric carcinoids. Am J Gastroenterol 1997;92:633-638. 
  28. Dallal HJ, Ravindran R, King PM, Phull PS. Gastric carcinoid tumour as a cause of severe upper gastrointestinal haemorrhage. Endoscopy 2003;35:716. 
  29. Rindi G, Azzoni C, La Rosa S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999;116:532-542.  https://doi.org/10.1016/S0016-5085(99)70174-5
  30. Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19:839-868.  https://doi.org/10.6004/jnccn.2021.0032
  31. Singh S, Law C. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 2012;6:313-334.  https://doi.org/10.1586/egh.12.15
  32. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017;67:93-99.  https://doi.org/10.3322/caac.21388
  33. Dias AR, Azevedo BC, Alban LBV, et al. Gastric neuroendocrine tumor: review and update. Arq Bras Cir Dig 2017;30:150-154.  https://doi.org/10.1590/0102-6720201700020016
  34. Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer 2005;103:1587-1595.  https://doi.org/10.1002/cncr.20939
  35. Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95:157-176.  https://doi.org/10.1159/000335597
  36. Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008;93:1582-1591.  https://doi.org/10.1210/jc.2007-2279
  37. Scherubl H, Cadiot G, Jensen RT, Rosch T, Stolzel U, Kloppel G. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy 2010;42:664-671.  https://doi.org/10.1055/s-0030-1255564
  38. Kulke MH, Shah MH, Benson AB 3rd, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw 2015;13:78-108.  https://doi.org/10.6004/jnccn.2015.0011
  39. Tsilimigras DI, Hyer JM, Paredes AZ, et al. Resection of primary gastrointestinal neuroendocrine tumor among patients with non-resected metastases is associated with improved survival: a SEER-Medicare analysis. J Gastrointest Surg 2021;25:2368-2376. https://doi.org/10.1007/s11605-020-04898-8